Dear Doctor,

We are conducting a Phase 3 clinical trial of Vedolizumab (Under name of VedAryo which is produced by AryoGen Pharmed) compared with the reference drug. If you have eligible patients, please kindly refer them to one of the trial centers.

Your collaboration will help provide patients with faster access to new and advanced treatments.

We sincerely appreciate your support.

With respect,

For any questions, please contact the study experts:

Dr. Afshin Zeinali – 09129729892 | Elham Gholizadeh – 09129571814

Please scan the QR code to see the list of clinical trial centers and obtain complete information about the study.

Orchid Pharmed
Sky's the Limit

VedAryo
Vedolizumab

Study Title

A phase III, randomized, two-armed, double-blind, parallel, active-controlled, non-inferiority clinical trial to compare efficacy and safety of Vedolizumab (AryoGen) versus Vedolizumab (Entyvio®, Takeda Inc.) in patients with moderate-to-severe Ulcerative Colitis between 18 to 75 years

Study Centers

City	Center
Tehran	6
Isfahan	2
Mashhad	2
Yazd	1
Sari	1
Rasht	1
Ahvaz	1
Bandar Abbas	1
Shiraz	1



Total Cities	9
Total Centers	16

Physicians

01 Dr. Reza Malek Zade (PI) (Shariati Hospital-Tehran)

02 Dr. Homayoun Vahedi (CO-PI) (Shariati Center-Tehran)

03 Dr. Naser Ebrahimi Daryani (Imam Khomeini Hospital-Tehran)

04 Dr. Foroogh Alborzi (Imam Khomeini Hospital-Tehran)

05 Dr. Farhad Zamani (Firoozgar Hospital-Tehran)

06 Dr. Shabnam Shahrokh (Taleghani Hospital-tehran)

07 Dr. Fariborz Mansour-Ghanaei (Guilan Gastroenterology and Hepatology Clinic-Rasht)

08 Dr. Iraj Maleki (Imam Khomeini Hospital-Sari)

09 Dr. Ali Akbar Shayesteh (Imam Khomeini Center-Ahvaz)

10 Dr. Hamid Mohajer (Shariati Hospital-Isfahan)

11 Dr. Babak Tamizifar (Dr. Babak Tamizifar's Medical Office-Isfahan)

12 Dr. Seyed Hamid Mousavi (Dr. Seyed Hamid Mousavi Clinic-Bandar Abbas)

13 Dr. Alireza Sima (Masoud Clinic-Tehran)

14 Dr. Shahram Agah (Agah Clinic-Tehran)

15 Dr. Ali Behesti (Qaem Hospital-Mashhad)

16 Dr. Mohammad Masoud Malekzadeh (Imam Reza Hospital-Mashhad)

17 Dr. Shahab Rahimpour (Dr. Shahab Rahimpour Clinic-Yazd)

18 Dr. Kamran Bagheri Lankarani – Faghihi Hospital Shiraz

19 Dr. Ali Shahsavari-Faghihi Hospital Shiraz

Inclusion Criteria

Patients aged 18–75 years (inclusive) at the time of signing the informed consent form

Patients who have been diagnosed with ulcerative colitis based on ACG guideline for at least 6 months and have one of these conditions:

a) No history of previous treatment with biologics

b) History of anti-TNF therapy or failure

Patients with moderate to severe active ulcerative colitis having Mayo score between 6 to 12 (Mayo endoscopic subscore of at least 2 based on colonoscopy)

Ability to comprehend and willingness to sign the informed consent form for this study and adherence to the study protocol principles

Exclusion Criteria

Have a history of known serious allergies to any components of the formulation

History or indication of extensive colonic surgery including subtotal or total colectomy

Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine

Diagnosis of indeterminate colitis, Crohn's disease, or clinical findings suggestive of Crohn's disease (i.e., fistula or granulomas)

Evidence of abdominal abscess or history of toxic megacolon disease

History, evidence of or treatment for Clostridium difficile infection within 8 weeks or other intestinal pathogens within 4 weeks prior to the study enrollment

Having adenomatous colonic polyps

Evidence of colonic mucosal dysplasia or its history

Ulcerative Colitis limited to only the rectum (Proctitis)

Previous treatment with Vedolizumab or Natalizumab

Previous treatment with Rituximab within 1 year prior to the study enrollment

Exclusion Criteria

Treatment failure with other biologics (Infliximab, Ustekinumab, Certolizumab pegol, and etc.) within 4 weeks prior to the study enrollment

Previous treatment with Thalidomide, Cyclosporine, Tacrolimus or JAK inhibitors within 4 weeks prior to the study enrollment

Previous treatment with natural or traditional medicines for gastrointestinal diseases within 2 weeks prior to the study enrollment

Immunization with a live/attenuated vaccine less than 4 weeks before baseline visit or planning to receive these vaccines during the study

Having hepatitis B, C or human immunodeficiency virus (HIV) infection

Active or latent tuberculosis based on PPD >5 mm or positive IGRA test

- The patients would not be enrolled in case of a positive result for either PPD or IGRA.
- If any of these tests were unavailable, the result of one test would suffice for enrollment.
- The patients who have received complete treatment for latent TB prior to enrolling in the study can participate.

Exclusion Criteria

Any identified congenital or acquired immunodeficiencies

Active infection or history of hospitalization or receiving injectable antibiotics within 8 weeks, or oral antibiotics within 2 weeks prior to baseline visit (rather than antibiotics indicated for UC)

Diagnosis of other autoimmune diseases

Currently has a known malignancy or has a history of malignancy

History of PML

Abnormalities during screening in laboratory data including:

- Corrected hemoglobin < 8 g/dL
- White blood cells < 3×10^9/L
- Lymphocyte count < 0.5×10^9/L
- Platelet count < 100×10^9/L or > 1200×10^9/L
- Aspartate Transaminase (AST) or Alanine Transaminase (ALT) ≥ 100 IU/L

Exclusion Criteria

Have had a substance abuse (drug or alcohol) problem within the previous 12 months prior to the study enrollment due to investigator's opinion.

Is pregnant, nursing, or planning a pregnancy (both men and women) during the study

Treatment with any investigational agent in the past 4 weeks prior to baseline visit or passing less than five half-lives of the investigational agent (whichever is longer)

Having any other condition which, in the opinion of the investigator, will make the subject inappropriate for enrolling the study